文献速递淋巴瘤

淋巴瘤临床试验成功率:2000年至2019年试验与药物的命运

Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019.
PubMed 文献 · Blood Adv · 2026-01-01

该研究基于Trialtrove数据库和ClinicalTrials.gov,分析2000年1月1日至2019年12月31日启动的淋巴瘤临床试验,评估在研药物跨期转化率及美国食品药品监督管理局(FDA)批准率。共识别1032项1期试验和510项1/2期试验,涉及651种不同药物;1期至2期转化率为30.7%,2期至3期转化率为23.0%,总批准率为6.1%,从首次1期试验启动至获批平均需7.9年。作者认为淋巴瘤1期试验的低批准率提示需改进试验设计并通过临床前研究预测临床反应以提高成功可能性。

要点

  • 2000-2019年淋巴瘤领域共开展1032项1期、510项1/2期、1027项2期、20项2/3期和140项3期试验。
  • 药物从1期推进至2期的成功率为30.7%,从2期推进至3期的成功率为23.0%。
  • 共40种药物获FDA批准,总批准率为6.1%,从首次1期试验至获批平均7.9年。

核心结论

  • 淋巴瘤1期试验至获批的批准率低,作者认为提示需改进试验设计并通过临床前研究预测临床反应以提高成功可能性。

研究设计与样本

  • 基于Trialtrove数据库和ClinicalTrials.gov分析2000年1月1日至2019年12月31日启动的淋巴瘤临床试验。
  • 纳入包含淋巴瘤患者的1期、2期和3期试验,分析在研药物跨期转化率及FDA批准率。

主要发现

  • 共开展1032项1期试验和510项1/2期试验,研究期间共评估651种不同药物。
  • 共开展1027项2期、20项2/3期和140项3期试验,200种药物从1期推进至2期,46种药物从2期推进至3期。
  • 药物从1期至2期和从2期至3期的成功率分别为30.7%和23.0%。
  • 共40种药物获FDA批准,总批准率为6.1%。
  • 从首次1期试验启动至淋巴瘤治疗获批的平均时间为7.9年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although previous studies have examined the drug development and clinical trial success rates in oncology, a comprehensive analysis of development success rate in lymphoma has not been performed. Therefore, we analyzed lymphoma trials initiated between 1 January 2000 and 31 December 2019, using the Trialtrove database and ClinicalTrials.gov. We identified phase 1, 2, and 3 trials that included patients with lymphoma and analyzed the transition rate of investigational agents across phases and their US Food and Drug Administration (FDA) approval rates to assess the efficiency and success of the clinical development process. A total of 1032 phase 1 trials and 510 phase 1/2 trials were conducted, with a total of 651 distinct agents being evaluated during the study period. There were 1027 phase 2, 20 phase 2/3, and 140 phase 3 trials conducted for lymphoma, with 200 agents proceeding from phase 1 to 2 and 46 agents proceeding from phase 2 to 3. The success rates of agents proceeding from phase 1 to 2 and phase 2 to 3 were 30.7% and 23.0%, respectively. A total of 40 agents reached FDA approval, with an overall approval rate of 6.1%. The average time from initiation of the first phase 1 trial to approval for lymphoma treatment was 7.9 years. Our study characterizes the clinical development landscape and timeline of novel therapies for lymphoma. Low approval rate from phase 1 trials in lymphoma suggests the need for improvement in trial design and in prediction of clinical response through preclinical studies to improve the likelihood of success.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Luo Z, Li M, Primeaux BC, et al. Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019. Blood Adv. 2026. PMID: 41201381. doi:10.1182/bloodadvances.2025017752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。